Table 4 Leading mRNA vaccine developers: research focus, partners and therapeutic platforms

From: mRNA vaccines — a new era in vaccinology

Institution mRNA technology Partners Indication (disease target)
Argos Biotechnology mRNA neoantigens (Arcelis platform) NA Individualized cancer vaccines, HIV-1
BioNTech RNA Pharmaceuticals GmbH Nucleoside-modified mRNA (IVAC Mutanome, FixVAC) Genentech/Roche Individualized cancer vaccines
Bayer AG Veterinary vaccines
CureVac AG Sequence-optimized, purified mRNA (RNActive, RNArt, RNAdjuvant) Boehringer Ingelheim GmbH Cancer vaccines (lung cancer)
Johnson & Johnson Viral vaccines
Sanofi Pasteur Infectious disease vaccines
BMGF Infectious disease vaccines
IAVI HIV vaccines
eTheRNA Immunotherapies Purified mRNA (TriMix) NA Cancer (melanoma, breast), viral vaccines (HBV and/or HPV)
GlaxoSmithKline/Novartis Self-amplifying mRNA (SAM) (alphavirus replicon) NA Infectious disease vaccines
Moderna Therapeutics Nucleoside-modified mRNA Merck & Co. Individualized cancer vaccines, viral vaccines
BMGF, DARPA, BARDA Viral vaccines (influenza virus, CMV, HMPV, PIV, chikungunya virus, Zika virus)
University of Pennsylvania Nucleoside-modified, purified mRNA NA Infectious disease vaccines
  1. BARDA, Biomedical Advanced Research and Development Authority; BMGF, Bill & Melinda Gates Foundation; CMV, cytomegalovirus; DARPA, Defense Advanced Research Projects Agency; HBV, hepatitis B virus; HMPV, human metapneumovirus; HPV, human papillomavirus; IAVI, International AIDS Vaccine Initiative; NA, not available; PIV, parainfluenza virus.
PowerPoint slide